Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.

Companies / NovaGo Therapeutics

NovaGo Therapeutics

Series BUS
Facts
Year of incorporation
unknown
Revenue range (Form D)
unknown
Rounds on record
1
Disclosed raised
unknownsum of rounds with a disclosed amount only
Named investors
2
Financing history
1 rounds
  1. Sep 2, 2026
    Series B · amount undisclosed
    Pureos (lead) via Dominik EscherNeurimmune (lead)
    Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS) · “NovaGo Therapeutics Closes USD 30 Million Series B Financing to Advance Proof-of-Concept Study in Acute Spinal Cord Injury”
Investors on record
2 edges
People
0 officers, 0 directors
No officer or director on record.
Timeline
1
  1. Sep 2, 2026
    NovaGo Therapeutics announced Series B, led by Neurimmune, Pureos
    Round announced Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS)
Evidence
1 observations
Every observation on this company